# Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Study · id `cardio:ct-nct03353350` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03353350](<https://clinicaltrials.gov/study/NCT03353350>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03353350

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

## Technical summary

Registry record NCT03353350. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-05 (actual); primary completion 2020-01-29 (actual). Results posted on 2022-01-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 406 participants (enrolled count; ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Started: 2017-12-05 (actual) (ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Primary completion: 2020-01-29 (actual) (ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Completion: 2020-09-07 (actual) (ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Results first posted: 2022-01-18 (ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Countries: United States; Germany; Poland; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03353350, source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03353350-2022-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
- Acronym: AMPLITUDE-M
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): efpeglenatide (SAR439977)
- Intervention (Drug): placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial (`cardio:pubmed-35671039`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 34fde62ce63d1c78d8d30453a742969b20cce8036ff590412a65c58d4ee3ed2a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
